___

1. Richardson C, Silver ES. Management of supraventricular tachycardia in infants. Paediatr Drugs 2017; 19: 539-551.

2. Wu MH, Chen HC, Kao FY, Huang SK. Postnatal cumulative incidence of supraventricular tachycardia in a general pediatric population: a national birth cohort database study. Heart Rhythm 2016; 13: 2070-2075.

3. Spearman AD, Williams P. Supraventricular tachycardia in infancy and childhood. Pediatr Ann 2014; 43: 456-460.

4. Gilljam T, Jaeggi E, Gow RM. Neonatal supraventricular tachycardia: outcomes over a 27- year period at a single institution. Acta Paediatr 2008; 97: 1035-1039.

5. BET 2: Campbell M, Buitrago SR. Ice water immersion, other vagal manoeuvres or adenosine for SVT in children. Emerg Med J 2017; 34: 58-60.

6. de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015; 132(18 Suppl 2): S526-S542.

7. Getschman SJ, Dietrich AM, Franklin WH, Allen HD. Intraosseous adenosine. As effective as peripheral or central venous administration. Arch Pediatr Adolesc Med 1994; 148: 616-619.

8. Paul T, Bertram H, Bökenkamp R, Hausdorf G. Supraventricular tachycardia in infants, children and adolescents: diagnosis, and pharmacological and interventional therapy. Paediatr Drugs 2000; 2: 171-181.

9. Lewis J, Arora G, Tudorascu DL, Hickey RW, Saladino RA, Manole MD. Acute management of refractory and unstable pediatric supraventricular tachycardia. J Pediatr 2017; 181: 177-182.e2.

10. Lerman BB, Markowitz SM, Cheung JW, Liu CF, Thomas G, Ip JE. Supraventricular tachycardia: mechanistic insights deduced from adenosine. Circ Arrhythm Electrophysiol 2018; 11: e006953.

11. Singh S, McKintosh R. Adenosine. [Updated 2020 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. (Available from: https://www. ncbi.nlm.nih.gov/books/NBK519049/)

12. Díaz-Parra S, Sánchez-Yañez P, Zabala-Argüelles I, et al. Use of adenosine in the treatment of supraventricular tachycardia in a pediatric emergency department. Pediatr Emerg Care 2014; 30: 388-393.

13. Quail MA, Till J. Question 3 Does a higher initial dose of adenosine improve cardioversion rates in supraventricular tachycardia? Arch Dis Child 2012; 97: 177-179.

14. Daya MR, Leroux BG, Dorian P, et al; Resuscitation Outcomes Consortium Investigators. Survival after intravenous versus intraosseous amiodarone, lidocaine, or placebo in out-of-hospital shockrefractory cardiac arrest. Circulation 2020; 141: 188- 198.

15. Luck RP, Haines C, Mull CC. Intraosseous access. J Emerg Med 2010; 39: 468-475.

16. Derinoz O, Keles A. Powered intraosseous device (EZ-IO) for critically ill patients. Indian Pediatr 2013; 50: 689-691.

17. Rosenberg H, Cheung WJ. Intraosseous access. CMAJ 2013; 185: E238.

18. Frascone RJ, Jensen J, Wewerka SS, Salzman JG. Use of the pediatric EZ-IO needle by emergency medical services providers. Pediatr Emerg Care 2009; 25: 329- 332.

19. Shavit I, Hoffmann Y, Galbraith R, Waisman Y. Comparison of two mechanical intraosseous infusion devices: a pilot, randomized crossover trial. Resuscitation 2009; 80: 1029-1033.

20. Friedman FD. Intraosseous adenosine for the termination of supraventricular tachycardia in an infant. Ann Emerg Med 1996; 28: 356-358.

21. Goodman IS, Lu CJ. Intraosseous infusion is unreliable for adenosine delivery in the treatment of supraventricular tachycardia. Pediatr Emerg Care 2012; 28: 47-48.

22. Helleman K, Kirpalani A, Lim R. A novel method of intraosseous infusion of adenosine for the treatment of supraventricular tachycardia in an infant. Pediatr Emerg Care 2017; 33: 47-48